Amidated and non-amidated glucagon-like peptide-1 (GLP-1): Non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans

Regulatory Peptides

Volumn 77, Issue 1-3, 1998, Pages 83-87

  Wettergren, Andre ^a   Pridal, Lone ^b   Wøjdemann, Morten ^a   Holst, Jens Juul ^c  

^a Rigshospitalet   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Carboxyamidation; Enterogastrone; Peptide metabolism; Proglucagon derived peptides; Sham feeding

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPROTIN A; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE 1;

ADULT; AMIDATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN STABILITY; STOMACH ACID SECRETION;

ADULT; BACITRACIN; FEMALE; GASTRIC ACID; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; STOMACH;

EID: 0032538344     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(98)00044-5     Document Type: Article

References (34)

1. [1] Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and the two related peptides. Nature 1983;302:716-8.
2. [2] Holst JJ. Enteroglucagon. Annu Rev Physiol 1997;59:257-72.
3. [3] Ørskov C, Bersani M, Johnsen AH, Højrup P, Holst JJ. Complete sequences of glucagon-like peptide-1 (GLP-1) from human and pig small intestine. J Biol Chem, 1989;264:12826-9.
4. [4] Ørskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996;31:665-70.
5. [5] Kolligs F, Fehmann HC, Göke R, Göke B. Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin (9-39) amide. Diabetes 1995;44:16-9.
6. [6] Wang Z, Wang RM, Owji AA, Smith DM, Ghatei M, Bloom SR. Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 1995;95:417-21.
7. [7] Scrocchi LA, Brown TJ, MacLusky N, Brukbaker PL, Auerbach AB, Joyner A, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Medicine 1996;2:1254-8.
8. [8] Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 72-107amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73.
9. [9] Layer P, Holst JJ, Grandt D, Goebell H. Heal release of glucagonlike peptide-1 (GLP-1): association with inhibition of gastric acid in humans. Dig Dis Sci 1995;40:1074-82.
10. [10] Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Schmiegel WH. Inhibition of gastric emptying by physiological and pharmacological doses of exogenous glucagon-like peptide 1 (GLP-1) outweighs insulinotropic effects in healthy normoglycemic volunteers. Am J Physiol 1997;273:E981-8.
11. [11] Read N, French S, Cunningham K. The role of the gut in regulating food intake in man. Nutr Rev 1994;52:1-10.
12. [12] Eipper BA, Mains RE, Herbert E. Peptides in the nervous system. Trends Neurosci 1986;9:463-8.
13. [13] Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide-1 are synthesized in the rat intestine and pancreas. J Biol Chem 1990;265:8001-8.
14. [14] Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994;43:535-9.
15. [15] Kreil G. Occurrence, detection and biosynthesis of carboxy-terminal amides. Meythods Enzymol 1984;106:218-23.
16. [16] Ørskov C, Wettergren A, Holst JJ. Effects and metabolic rates effects of GLP-1 7-36amide and GLP-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993;42:658-61.
17. [17] Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-7.
18. [18] Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneous and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-31.
19. [19] Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide-1 undergoes differential tissue-specific metabolism in the anaesthetised pig. Am J Physiol 1996;271:E458-64.
20. [20] Holst JJ, Wettergren A, Wøjdemann M, Poulsen SS, Ørskov C. Glucagon-like peptide-1 (GLP-1): an important enterogastrone acting via the central nervous system. Hepatogastroenterology 1995;42:1071.
21. [21] Fung LC, Chisholm C, Greenberg GR. Glucagon-like peptide-1 (7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs. Endocrinology 1998;139:189-94.
22. [22] Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide-1 (GLP-1) 7-36 amide and peptide YY from the L-cell in the ileal mucosa are potent inhibitors of vagally induced gastric acid in man. Scand J Gastroenterol 1994;29:501-5.
23. [23] Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 7-36amide on gastric acid secretion in man depends on an intact vagal innervation. Gut 1997;40:597-601.
24. [24] Ørskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of non-insulin dependent diabetics and nondiabetic controls in the fasting state and following oral glucose and intravenous arginine. J Clin Invest 1991;187:415-23.
25. [25] Pridal L, Ingwersen SH, Larsen FS, Holst JJ, Adelhorst K, Kirk O. Comparison of sandwich ELISA and RIA for determination of exogenous GLP-1 (7-36 amide) in plasma. J Pharmaceutical and Biomedical Analysis 1995;13:841-50.
26. [26] Heinzel G, Woloszczak R, Thomann P. Pharmacokinetic and pharmacodynamic data analysis system for the PC. Topfit 2.0. Gustac Fisher, Stuttgart, Germany 1993.
27. [27] Holst JJ, Rasmussen TN, Harling H, Schmidt P. Effect of intestinal inhibitory peptides on vagally induced secretion from isolated perfused porcine pancreas. Pancreas 1993;8:80-7.
28. [28] Nakabayshi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 1996;271:E808-13.
29. [29] Thorens B, Porret A, Bühler L, Deng S-H, Morel P, Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin 4 is an agonist and exendin 9-39 an antagonist of the receptor. Diabetes 1993;42:1678-82.
30. [30] Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-24.
31. [31] Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagonlike peptide-1 (7-36) amide, peptide histidine methionine and is resposible for their degradation in human serum. Eur J Biochem 1993;214:829-35.
32. [32] Zollner H. Handbook of Enzyme Inhibitors. Basel: Weinheim, 1993.
33. [33] Hupe-Sodman K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, Zimmermann B, Voigt K. Characterization of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36) amide and comparison of the substrate specificity of the enzymes for other glucagon-like peptides. Regul Pept 1995;58:149-56.
34. [34] Hilsted L, Hint K, Christiansen J, Rehfeld JF. Neither glycin-extended gastrin nor the 1-13 fragment of gastrin-17 influences gastric acid secretion in humans. Gastroenterology 1988;94:96-102.